History of worsening heart failure and outcomes with vericiguat in ambulatory HFrEF: an exploratory post-hoc analysis of VICTOR
Stefan Störk, Javed Butler, Caroline Morbach, Fabian Kerwagen, Johann Bauersachs, Ephraim B Winzer, Justin Ezekowitz, Carolyn S P Lam, Inga Bayh, Stefan He
Authors
- Johann Bauersachs (ORCID: https://orcid.org/0000-0002-9341-117X)
- Stefan Herrmann (ORCID: https://orcid.org/0000-0002-4473-9224)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Fabian Kerwagen (ORCID: https://orcid.org/0000-0002-6501-7511)
- Inga Bayh
- Irina Barash (ORCID: https://orcid.org/0000-0002-0358-6591)
- Javed Butler (ORCID: https://orcid.org/0000-0003-4267-6933)
- Stefan Störk (ORCID: https://orcid.org/0000-0002-1771-7249)
- Caroline Morbach (ORCID: https://orcid.org/0000-0002-0920-6094)
- Carolyn S.P. Lam
- Justin Ezekowitz
- Ephraim B Winzer
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Alberta (CA)
- Medizinische Hochschule Hannover (DE)
- University of Mississippi (US)
- National University Heart Centre Singapore (SG)
- Canadian VIGOUR Centre (CA)
- Universitätsklinikum Würzburg (DE)
- National Heart Centre Singapore (SG)
- Baylor Scott & White Health (US)
- Bayer (Germany) (DE)
- Technische Universität Dresden (DE)
- Université de Lorraine (FR)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2026-08-28
- DOI
- https://doi.org/10.1093/ejhf/xuag262
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer